CRBP Corbus Pharmaceuticals Holdings Inc
- Stocks
- Healthcare
- NASDAQ: CRBP
Price (delayed)
$9
Market cap
$110.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.74
Enterprise value
$92.04M
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is
Highlights
CRBP's debt has dropped by 83% year-on-year and by 14% since the previous quarter
The quick ratio rose by 43% YoY but it fell by 23% QoQ
Corbus Pharmaceuticals Holdings's EPS has increased by 18% YoY but it has decreased by 13% QoQ
Corbus Pharmaceuticals Holdings's net income has plunged by 66% YoY and by 15% from the previous quarter
The company's equity fell by 13% QoQ and by 12% YoY
Key stats
What are the main financial stats of CRBP
Market
Valuations
Earnings
Shares outstanding
12.26M
Market cap
$110.3M
Enterprise value
$92.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.99
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$67.04M
Net income
-$57.95M
EBIT
-$57.57M
EBITDA
-$57.15M
Free cash flow
-$57.9M
Per share
Balance sheet
Liquidity
EPS
-$4.74
EPS diluted
-$4.74
Free cash flow per share
-$4.73
Book value per share
$9.07
Revenue per share
$0
TBVPS
$10.22
Total assets
$125.09M
Total liabilities
$14.09M
Debt
$2.46M
Equity
$110.99M
Working capital
$109.49M
Debt to equity
0.02
Current ratio
9.21
Quick ratio
8.79
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-39.6%
Return on equity
-43.7%
Return on invested capital
-48.9%
Return on capital employed
-51.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRBP stock price
How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
-1.21%
1 week
-2.91%
1 month
23.29%
1 year
-81.37%
YTD
-23.73%
QTD
30.43%
Financial performance
How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$67.04M
Net income
-$57.95M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 67% year-on-year and by 14% since the previous quarter
Corbus Pharmaceuticals Holdings's net income has plunged by 66% YoY and by 15% from the previous quarter
Price vs fundamentals
How does CRBP's price correlate with its fundamentals
Growth
What is Corbus Pharmaceuticals Holdings's growth rate over time
Valuation
What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
0.99
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Corbus Pharmaceuticals Holdings's EPS has increased by 18% YoY but it has decreased by 13% QoQ
CRBP's P/B is 86% below its 5-year quarterly average of 6.9
The company's equity fell by 13% QoQ and by 12% YoY
Efficiency
How efficient is Corbus Pharmaceuticals Holdings business performance
The ROE rose by 33% YoY but it fell by 18% QoQ
CRBP's return on invested capital is down by 23% since the previous quarter but it is up by 7% year-on-year
The ROA has decreased by 20% from the previous quarter but it has increased by 3.2% YoY
Dividends
What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRBP.
Financial health
How did Corbus Pharmaceuticals Holdings financials performed over time
Corbus Pharmaceuticals Holdings's current ratio has increased by 49% YoY but it has decreased by 22% QoQ
CRBP's total liabilities is down by 47% YoY but it is up by 10% from the previous quarter
CRBP's debt is 98% smaller than its equity
CRBP's debt to equity has dropped by 83% year-on-year
CRBP's debt has dropped by 83% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.